An oral live attenuated vaccine strategy against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV)

An oral live attenuated vaccine strategy against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV)

Madhusudana Girija Sanal, Ravi Chandra Duby

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV) infection has become a pandemic called COVID-19. The virus binds to angiotensin converting enzyme 2 (ACE2) and TMPRSS2 which are abundantly expressed on various human cells including lung epithelial cells and intestinal cells and the virus can infect these cells. Currently no specific treatments or vaccines are available for this disease. A per oral live attenuated vaccine can be a good strategy in SARS-CoV-2 infection because the attenuated virus initially infects the gut, stimulates the mucosa associated immune system sparing the respiratory system during the initial immune response. The live virus can also spread in the community boosting herd immunity.

2020

Oral Live Attenuated Vaccine, Severe Acute Respira

DOI: 10.3897/rio.6.e53767

Research Ideas and Outcomes

Pensoft Publishers

Science